Ask AI
ProCE Banner Activity

FAQs: Adopting the Latest Guidelines in MM

Clinical Thought

In this commentary, experts who serve on the National Comprehensive Cancer Network MM guideline panel address questions on the latest clinical developments and guideline updates focusing on recent and emerging treatment advances in the personalization of care of patients with smoldering and symptomatic multiple myeloma.

Released: July 08, 2026

Share

Provided by

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Decera Clinical Education.

ProCE Banner

Supporters

AstraZeneca

GSK

Johnson & Johnson

Partners

Decera Clinical Education

ProCE Banner

Target Audience

This program is intended for hematologists, oncologists, advance practice providers, nurses, pharmacists, and other healthcare professionals who care for patients with multiple myeloma. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Initiate timely systemic treatment for appropriate patients based on the latest multiple myeloma diagnosis, staging criteria, and risk factors
  • Develop individualized treatment strategies for patients with newly diagnosed multiple myeloma through consideration of the available clinical data, as well as risk assessment, comorbidities, and patient age/fitness and preferences
  • Select optimal sequencing and bridging therapies for patients with relapsed/refractory multiple myeloma based on individual patient and disease characteristics, as well as NCCN Guideline recommendations and response to and tolerance of previous therapies

Financial Disclosures

Primary Author

Natalie S. Callander, MD, has no relevant financial relationships to disclose.

Carol Ann Huff, MD: consultant/advisor/speaker: Alexion, Bristol Myers Squibb, Johnson & Johnson, Legend Biotechnologies, Prothena, Sanofi; researcher: Johnson & Johnson.

Mark A. Schroeder, MD, MSCI: data and safety monitoring board: Advarra, Kura Oncology, Marker Therapeutics, Sorrento; other financial or material support: GSK, IQVIA, Novo Nordisk, Parexel; advisor: Sanofi.